Bayer MaterialScience Bayer MaterialScience

Contact Search Sitemap
Home Products Industries & Applications Our Businesses Processing/Design News & Events Resources
Bayer Links



For Immediate Release

Bayer MaterialScience LLC Introduces Company’s First Medical-grade PC/ABS Blends at MD&M West 2007


Bayblend® DP M850 and Bayblend DP M850XF PC/ABS Blends Expand Bayer MaterialScience’s Portfolio of Medical-grade Polymers


February 12, 2007

PITTSBURGH, Feb. 12, 2007 — Bayer MaterialScience LLC (BMS) has expanded its offering of Bayblend® PC/ABS (polycarbonate/acrylonitrile-butadiene-styrene) blend resins with the introduction of Bayblend® DP M850 and Bayblend® DP M850XF resins. BMS announced the launch of these new materials — the company's first medical-grade PC/ABS blends — at MD&M West 2007.

These new grades, which join BMS' existing family of Bayblend resins, offer a favorable combination of properties, including impact resistance, rigidity, dimensional stability, color stability, thermal stability and processability. Most importantly, the new grades also meet the requirements of the FDA-modified ISO 10933, Part 1 tests for biocompatibility. Acceptable sterilization methods for these new Bayblend medical grades include ethylene oxide (EtO), gamma radiation, and electron beam radiation.

Both new Bayblend grades are recommended for opaque medical applications, such as components for surgical instruments, diagnostic devices, drug delivery systems and IV systems. Bayblend DP M850XF PC/ABS blend, an easy flow grade, is particularly well suited for molding of thin-wall components.

"Bayer MaterialScience developed these new Bayblend grades in response to a growing need for engineering polymers that offer the balance of processability and physical properties required for components of medical devices and diagnostic equipment," explained Kevin Dunay, BMS LLC NAFTA Market Segment Leader for Medical. "These new medical-grade Bayblend resins fill this performance gap."

According to Dunay, medical product manufacturers already rely on BMS for engineering polymers that meet critical design, manufacturing and end-use performance parameters. These polymers include Makrolon® polycarbonate, Apec® high-heat polycarbonate, Makroblend® polycarbonate/polyester blends, and Texin® thermoplastic polyurethanes (TPU). "We're pleased to be able to expand our proven portfolio of materials for medical applications with the introduction of Bayblend DP M850 and Bayblend DP M850XF PC/ABS blend resins," he said.

For more information about BMS' portfolio of engineering resins for the medical market, call 1-800-662-2927 or visit www.bayermaterialscienceNAFTA.com.

Bayer MaterialScience LLC is one of the leading producers of polymers and high-performance plastics in North America and is part of the global Bayer MaterialScience business with nearly 19,000 employees at 40 sites around the world and 2005 sales of 10.7 billion euros. Our innovative developments in coating, adhesive and sealant raw materials, polycarbonates, polyurethanes and thermoplastic urethane elastomers enhance the design and functionality of products in a wide variety of markets, including the automotive, construction, electrical and electronics, household and medical industries, and the sports and leisure fields. Our inorganic basic chemicals unit produces chlorine and related essential products for the chemicals industry. Let us give life to your vision. Bayer MaterialScience — Where VisionWorks.

Bayer Corporation, headquartered in Pittsburgh, is a subsidiary of Bayer AG, an international health care, nutrition and innovative materials group based in Leverkusen, Germany. In North America, Bayer had 2005 net sales of 7.3 billion euros and employed 16,200 at year end. Bayer's three operating companies — Bayer HealthCare LLC, Bayer CropScience LP and Bayer MaterialScience LLC — improve people's lives through a broad range of essential products that help diagnose, prevent and treat diseases, protect crops and advance automobile safety and durability.

# # #

This website may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


Media Contact(s)
Name: Scott Hunsberger
Phone: 412-777-5200
Company: Bayer MaterialScience
Email: scott.hunsberger@bayerbms.com








Site Map